abstract |
The present invention discloses recombinant human antibodies that recognize the human vascular endothelial growth factor A(VEGF-A), block the interaction thereof with the VEGFR2 receptor, and interfere with the in vitro proliferative and in vivo pro-angiogenic effects thereof. Said antibodies identify an epitope in the human VEGF-A that is different from any other one previously reported and were obtained by combining a single immunoglobulin light chain variable region with three other heavy chain regions. The antibodies were obtained by means of mutagenesis of human immunoglobulin variable regions, and can be used for immunotherapy for pathological entities associated with vascular growth, such as age-related macular degeneration, cancer and others. |